Investigating the effects of a medication for obesity on heart and metabolic health in young people with type 1 diabetes
Official title: Obesity complicating type 1 diabetes in young people: Physiology and Impact of GLP-1 analogue anti-obesity treatment on cardiometabolic risk factors
Funded at Yale University · NIH-10898805 · Data updated 2026-11-12
This study is looking at how a special medication can help young people with type 1 diabetes manage their weight and improve their health, by checking things like body fat and how their bodies use insulin.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $698,781 |
| NIH project number | 5R01DK134398-02 |
| Project ID | NIH-10898805 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescents and young adults diagnosed with type 1 diabetes who are also experiencing obesity.
✕Less likely to help
Patients without type 1 diabetes or those who are not struggling with obesity may not benefit from this research.
What this research studies
This research focuses on understanding how a GLP-1 analogue medication can help manage obesity and its related health risks in young individuals with type 1 diabetes. The study will assess various physiological factors, including fat distribution and insulin resistance, using advanced imaging techniques and metabolic tests. By examining these factors, the research aims to determine how effective this treatment is in reducing cardiometabolic risks associated with obesity in this population. Participants will undergo several assessments, including MRI scans and metabolic testing, to gather comprehensive data on their health.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for young people with type 1 diabetes and obesity, potentially reducing their risk of cardiovascular diseases.
How similar studies have gone: Previous research has shown promising results with GLP-1 analogue treatments in managing obesity and metabolic health, indicating potential for success in this study.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Van Name, Michelle — Yale University
- Study coordinator: Van Name, Michelle
Related research
Other NIH-funded projects on the same topics.
-
Obesity and GLP-1 treatment in young people with type 1 diabetes
A study in teens and young adults with type 1 diabetes and obesity will look at how a GLP-1–based obesity medicine affects body fat distribution, insulin resistance, and lipids.
-
Understanding and treating obesity in young people with type 1 diabetes
This research explores how a medication for obesity, called a GLP-1 analogue, helps young people with type 1 diabetes manage their weight and reduce heart-related health risks.
-
Low-cost, heat-stable GLP-1 and GIP receptor agonists produced in maize for diabetes and obesity
This project aims to make affordable, heat-stable versions of diabetes and obesity medicines using corn plants.
-
Understanding what raises heart disease risk in people with well-controlled type 1 diabetes
Researchers are studying why some people with type 1 diabetes still develop heart disease even when traditional risk factors are controlled.
-
Comparing bariatric (weight‑loss) surgery with GLP‑1 and SGLT‑2 diabetes medicines for people with obesity and type 2 diabetes
This project compares long-term benefits and safety of weight‑loss surgery versus GLP‑1 and SGLT‑2 diabetes medicines for adults who have obesity and type 2 diabetes.
-
Understanding Heart Disease Risks in People with Well-Controlled Type 1 Diabetes
This project looks at why people with Type 1 diabetes might still get heart disease, even when their other health factors are well-managed.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.